OncoSec Medical Inc (ONCSQ)

[hschlauch]

I think T-Vec has a hard time dealing with visceral lesions, even in combination. I wasn't too impressed with their monotherapy data, but their most recent combo trial results were okay for metastatic melanoma. T-Vec is able to prime tumors for checkpoint inhibitors in all comers, which is probably why they have seen decent results, i.e. 62% responses (n=21). These results, however, are comparable to many other combination treatments with checkpoint inhibitors in all comers; these aren't anti-pd-1 failures, so it's difficult to compare these results with Oncosec's.